Nat Commun:VAV2促进皮肤和头颈部鳞状细胞癌的再生性增殖

2020-09-24 xiaozeng MedSci原创

皮肤鳞状细胞癌(cSCC)和头颈部鳞状细胞癌(hnSCC)是分别从皮肤的分层上皮和上消化道的粘膜内层发生的癌症。在全球范围内,由于其升高的发病率,高侵袭性,较差的疾病预后以及有限的治疗手段和效果,如今

皮肤鳞状细胞癌(cSCC)和头颈部鳞状细胞癌(hnSCC)是分别从皮肤的分层上皮和上消化道的粘膜内层发生的癌症。在全球范围内,由于其升高的发病率,高侵袭性,较差的疾病预后以及有限的治疗手段和效果,如今已成为一大临床挑战。这些癌症发生的危险因素包括紫外线照射(对于cSCC);饮酒、吸烟和HPV(人乳头瘤病毒)感染(对于hnSCC)。

再生性增殖能力以及较差的分化能力通常是hnSCC不良预后的相关组织学特征。然而,其潜在的调节仍然未知。该研究揭示了上述特性可由皮肤和口腔粘膜的角质形成细胞中的RHO GTPase激活因子VAV2所诱发。且这些特性的维持也同样依赖VAV2。

上调VAV2信号具有促癌作用

研究人员发现,该催化依赖性以及RHO GTPase依赖性功能是由c-Myc和YAP/TAZ依赖性的再生性增殖和细胞未分化相关转录所介导的。进一步研究显示,VAV2的高转录水平和VAV2调控的相关特征基因的高表达水平均对应hnSCC患者的不良预后。


综上,该研究结果提示,VAV2相关信号通路或可成为特定的鳞状细胞癌亚型恶性肿瘤的潜在治疗靶标。


原始出处:

Lorenzo-Martín, L.F., Fernández-Parejo, N., Menacho-Márquez, M. et al. VAV2 signaling promotes regenerative proliferation in both cutaneous and head and neck squamous cell carcinoma. Nat Commun 11, 4788 (22 September 2020).

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1884682, encodeId=4e0a1884682c4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 29 03:11:19 CST 2020, time=2020-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979024, encodeId=03eb19e902470, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sat Mar 06 16:11:19 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087784, encodeId=6e08208e784b9, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Jul 19 13:11:19 CST 2021, time=2021-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297708, encodeId=74bf129e708f1, content=<a href='/topic/show?id=f999444352f' target=_blank style='color:#2F92EE;'>#头颈部鳞状细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44435, encryptionId=f999444352f, topicName=头颈部鳞状细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Sep 26 13:11:19 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491876, encodeId=b3dc14918e66f, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Sat Sep 26 13:11:19 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589845, encodeId=0f581589845f5, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Sat Sep 26 13:11:19 CST 2020, time=2020-09-26, status=1, ipAttribution=)]
    2020-09-29 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1884682, encodeId=4e0a1884682c4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 29 03:11:19 CST 2020, time=2020-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979024, encodeId=03eb19e902470, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sat Mar 06 16:11:19 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087784, encodeId=6e08208e784b9, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Jul 19 13:11:19 CST 2021, time=2021-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297708, encodeId=74bf129e708f1, content=<a href='/topic/show?id=f999444352f' target=_blank style='color:#2F92EE;'>#头颈部鳞状细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44435, encryptionId=f999444352f, topicName=头颈部鳞状细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Sep 26 13:11:19 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491876, encodeId=b3dc14918e66f, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Sat Sep 26 13:11:19 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589845, encodeId=0f581589845f5, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Sat Sep 26 13:11:19 CST 2020, time=2020-09-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1884682, encodeId=4e0a1884682c4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 29 03:11:19 CST 2020, time=2020-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979024, encodeId=03eb19e902470, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sat Mar 06 16:11:19 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087784, encodeId=6e08208e784b9, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Jul 19 13:11:19 CST 2021, time=2021-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297708, encodeId=74bf129e708f1, content=<a href='/topic/show?id=f999444352f' target=_blank style='color:#2F92EE;'>#头颈部鳞状细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44435, encryptionId=f999444352f, topicName=头颈部鳞状细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Sep 26 13:11:19 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491876, encodeId=b3dc14918e66f, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Sat Sep 26 13:11:19 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589845, encodeId=0f581589845f5, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Sat Sep 26 13:11:19 CST 2020, time=2020-09-26, status=1, ipAttribution=)]
    2021-07-19 liuli5079
  4. [GetPortalCommentsPageByObjectIdResponse(id=1884682, encodeId=4e0a1884682c4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 29 03:11:19 CST 2020, time=2020-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979024, encodeId=03eb19e902470, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sat Mar 06 16:11:19 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087784, encodeId=6e08208e784b9, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Jul 19 13:11:19 CST 2021, time=2021-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297708, encodeId=74bf129e708f1, content=<a href='/topic/show?id=f999444352f' target=_blank style='color:#2F92EE;'>#头颈部鳞状细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44435, encryptionId=f999444352f, topicName=头颈部鳞状细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Sep 26 13:11:19 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491876, encodeId=b3dc14918e66f, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Sat Sep 26 13:11:19 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589845, encodeId=0f581589845f5, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Sat Sep 26 13:11:19 CST 2020, time=2020-09-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1884682, encodeId=4e0a1884682c4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 29 03:11:19 CST 2020, time=2020-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979024, encodeId=03eb19e902470, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sat Mar 06 16:11:19 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087784, encodeId=6e08208e784b9, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Jul 19 13:11:19 CST 2021, time=2021-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297708, encodeId=74bf129e708f1, content=<a href='/topic/show?id=f999444352f' target=_blank style='color:#2F92EE;'>#头颈部鳞状细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44435, encryptionId=f999444352f, topicName=头颈部鳞状细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Sep 26 13:11:19 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491876, encodeId=b3dc14918e66f, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Sat Sep 26 13:11:19 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589845, encodeId=0f581589845f5, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Sat Sep 26 13:11:19 CST 2020, time=2020-09-26, status=1, ipAttribution=)]
    2020-09-26 wshxjq
  6. [GetPortalCommentsPageByObjectIdResponse(id=1884682, encodeId=4e0a1884682c4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 29 03:11:19 CST 2020, time=2020-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1979024, encodeId=03eb19e902470, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sat Mar 06 16:11:19 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087784, encodeId=6e08208e784b9, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Jul 19 13:11:19 CST 2021, time=2021-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297708, encodeId=74bf129e708f1, content=<a href='/topic/show?id=f999444352f' target=_blank style='color:#2F92EE;'>#头颈部鳞状细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44435, encryptionId=f999444352f, topicName=头颈部鳞状细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Sep 26 13:11:19 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491876, encodeId=b3dc14918e66f, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Sat Sep 26 13:11:19 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589845, encodeId=0f581589845f5, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Sat Sep 26 13:11:19 CST 2020, time=2020-09-26, status=1, ipAttribution=)]

相关资讯

NCCN临床实践指南:皮肤鳞状细胞癌(2019.V2)

2018年10月,美国国家综合癌症网络(NCCN)发布了皮肤鳞状细胞癌管理指南2019年第2版,指南主要内容包括: 皮肤鳞状细胞癌的检查和风险状态 皮肤鳞状细胞癌初级治疗和辅助治疗 皮肤鳞状细胞癌随访以及疾病进展 皮肤鳞状细胞癌的局部复发和转移的危险因素 皮肤鳞状细胞癌的治疗原则 高风险患者的识别和管理 分期

FDA批准赛诺菲和再生元的PD-1单抗Libtayo用于治疗晚期皮肤鳞状细胞癌

9月29日,FDA批准赛诺菲和再生元联合开发的PD-1单抗Libtayo(cemiplimab-rwlc)用于治疗不适合进行手术或放射治疗的转移性或局部晚期的皮肤鳞状细胞癌(CSCC) 患者。Libtayo是美国第一个批准用于晚期CSCC的治疗药物。

英国NICE批准Sanofi/Regeneron的PD-1单抗Libtayo用于治疗皮肤鳞状细胞癌

英国NHS批准Sanofi / Regeneron的新检查点抑制剂PD-1单抗Libtayo(cemiplimab),用于皮肤鳞状细胞癌(CSCC)患者的额治疗。成本效益监督机构已发布指南,建议由癌症药物基金会(CDF)资助Libtayo(cemiplimab)用于皮肤鳞状细胞癌(CSCC)。

NCCN临床实践指南:皮肤鳞状细胞癌(2019.V1)

2018年9月,美国国家综合癌症网络(NCCN)发布了皮肤鳞状细胞癌管理指南2019年第1版,指南主要内容包括: 皮肤鳞状细胞癌的检查和风险状态 皮肤鳞状细胞癌初级治疗和辅助治疗 皮肤鳞状细胞癌随访以及疾病进展 皮肤鳞状细胞癌的局部复发和转移的危险因素 皮肤鳞状细胞癌的治疗原则 高风险患者的识别和管理 分期

Stem cells:脐带血干细胞可预防隐形营养不良型大疱性表皮松解症恶性转变

隐形营养不良型大疱性表皮松解症(RDEB)是一种由Col7a1基因突变导致的严重的皮肤脆性疾病。RDEB患者遭受周期性的皮肤黏膜糜烂,具有高度发展成皮肤鳞状细胞癌(cSCCs)的风险。既往报道TGFβ信号与RDEB患者的纤维化和恶性肿瘤相关。研究发现早在col7a-/-小鼠一出生后爪子蹼中即可检测到TGFβ信号激活,伴随真皮内胶原纤维沉积增加、基质金属蛋白酶(MMP)-9和MMP-13的表达量增加

Lancet Oncol:Cemiplimab治疗局部晚期皮肤鳞状细胞癌

研究认为,Cemiplimab在局部晚期皮肤鳞状细胞癌患者中显示了良好的抗肿瘤活性和可接受的安全性